Oryzon Genomics S.A. (ORY.MC)

EUR 2.74

(-0.36%)

Total Liabilities Summary of Oryzon Genomics S.A.

  • Oryzon Genomics S.A.'s latest annual total liabilities in 2023 was 25.12 Million EUR , down -19.28% from previous year.
  • Oryzon Genomics S.A.'s latest quarterly total liabilities in 2024 Q3 was 25.8 Million EUR , up 6.82% from previous quarter.
  • Oryzon Genomics S.A. reported annual total liabilities of 31.12 Million EUR in 2022, up 29.04% from previous year.
  • Oryzon Genomics S.A. reported annual total liabilities of 24.12 Million EUR in 2021, up 32.72% from previous year.
  • Oryzon Genomics S.A. reported quarterly total liabilities of 25.8 Million EUR for 2024 Q3, up 6.82% from previous quarter.
  • Oryzon Genomics S.A. reported quarterly total liabilities of 24.15 Million EUR for 2024 Q2, up 4.26% from previous quarter.

Annual Total Liabilities Chart of Oryzon Genomics S.A. (2023 - 2019)

Historical Annual Total Liabilities of Oryzon Genomics S.A. (2023 - 2019)

Year Total Liabilities Total Liabilities Growth
2023 25.12 Million EUR -19.28%
2022 31.12 Million EUR 29.04%
2021 24.12 Million EUR 32.72%
2020 18.17 Million EUR 22797.11%
2019 79.38 Thousand EUR 0.0%

Peer Total Liabilities Comparison of Oryzon Genomics S.A.

Name Total Liabilities Total Liabilities Difference
Atrys Health, S.A. 332.45 Million EUR 92.442%
Biotechnologies Assets SA 10.07 Million EUR -149.374%
Pharma Mar, S.A. 147.78 Million EUR 82.999%
Laboratorios Farmaceuticos Rovi, S.A. 256.39 Million EUR 90.2%